Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Definitions

• the present invention relates to 5,6- dihydro-G-oxo-pyrido[2,3-b] [l,4]benzoxazepines of the formula W ⁇ AX i m wherein R and R which may be identical to or diiferent from each other, are hydrogen, halogen, lower alkyl, lower alkoxy, hydroxyl, acyloxy, amino, acylamino or acyl, or, together with each other and adjacent carbon atoms of the benzo-moiety to Which they are attached, may form an aromatic ring fused to said benzo-moiety, especially a fused benzene ring.
• a compound of the group embraced by Formula I may be prepared by reacting a 2-halo-3-amino-pyridine of the formula N Hal wherein Hal is a halogen, with a reactive derivative of a salicylic acid compound of the formula HOOC (III) wherein R and R have the same meanings as in Formula I and R is hydrogen or a protective group for phenolic hydroxyl, such as acyl or p-toluene sulfonyl.
• suitable reactive derivatives of a salicylic acid compound of the Formula III are its alkyl or aryl esters, its acid halides or anhydrides and the like. -In the event that R and R are hydroxyl or amino, they are advantageously protected with a protective group, such as acyl, prior to the performance of the reaction.
• the reaction between Compound II and the reactive derivative of Compound III is carried out at a temperature above 150 C. and, if desired, in the presence of an inert organic solvent having a relatively high boiling point, such as tetrahydronaphthalene, trichlorobenzene, decahydronaphthalene and the like.
• an inert organic solvent having a relatively high boiling point such as tetrahydronaphthalene, trichlorobenzene, decahydronaphthalene and the like.
• an intermediate compound of the formula Hal RaO (IV) wherein R R and R have the same meanings as in Formula I and Hal is halogen is formed initially at a temperature between 0 and 150 C.
• This intermediate product does not need to be isolated; instead, the reaction mixture containing it merely needs to be heated to a temperature above 150 C., preferably in the presence of a strong base and in the presence or absence of an inert solvent having a relatively high boiling point, to effect ring closure of the oxazepine ring and thereby form the desired end product of the Formula I.
• Example l.-Preparation of 5,6-dihydro-6-oxo-pyrido[2, 3-b] [1,4] benzoxazepine A mixture consisting of gm. (0.62 mol) of Z-chloro- 3-amino-pyridine, 86 gm. (0.4 mol) of phenyl salicylate and 80 cc. of trichlorobenzene was heated at its boiling point for one hour, accompanied by stirring and bubbling nitrogen therethrough. The phenol liberated by the reaction was continuously distilled off; the liberated gaseous hydrogen chloride was absorbed in a receiver charged with aqueous sodium hydroxide. Thereafter, while it was still hot, the reaction mixture was poured into about 400 cc.
• Example 2 Preparation of 5 ,6-dihydro-6-oxopyrido [2,3-b] [1,4] benzoxazepine through the intermediate 2- chloro-3-(2'-hydroxy-benzoylamino)-pyridine (a) 62.5 gm. (0.4 mol) of salicyclic acid chloride were dissolved in 500 cc. of absolute benzene, and the resulting solution was added dropwise at room temperature to a solution of 52 gm. (0.4 mol) of 2-chloro-3-amino pyridine in 500 cc. of benzene, accompanied by stirring. After all of the salicyclic acid chloride solution had been added, the reaction solution was refluxed for one hour.
• reaction solution was extracted by shaking with dilute aqueous sodium hydroxide, the aqueous alkaline phase was separated and filtered through activated charcoal, and then carbon dioxide gas was passed through the filtrate. A precipitate was formed, which was isolated and recrystallized from isopropanol.
• the reaction product had a melting point of l93195 C. (decomposition) and was identified to be 2-chloro3-(2- hydroxy-benzoylamino)-pyridine of the formula N 01 no Analysis.C, -H ClN O mol. wt. 248.7. Calculated:
• Example 3 (a) 109 gm. (0.55 mol) of acetylsalicylic acid chloride were dissolved in 500 cc. of absolute toluene, and the resulting solution was added dropwise to a boiling solution of 71 gm. (0.55 mol) of 2-chloro-3-aminopyridine in 1000 cc. of absolute toluene, accompanied by stirring. The resulting mixture was then refluxed for one hour and allowed to cool. A small amount of the intermediate product of Example 2(a) crystallized out, which was filtered off, and the filtrate was evaporated in vacuo.
• Example 4 Preparation of 5,6-dihydro-6-oxo-8-chloropyrido[2,3-b] [1,4]benzoxazepine
• a 0.1 mol of 5-chloro-acetyl salicylic acid chloride and 0.1 mol of 2-chloro3-amino-pyridine were refluxed for two hours in absolute xylene, as described in Example 3(a).
• 2-chloro3-amino-pyridine Upon cooling of the reaction solution, a small amount of 2 chloro-3-(2'-hydroxy-5-chloro-benzoylamino) -pyridine, ethanol), crystallized out.
• the precipitate was separated by filtration, the filtrate was evaporated in vacuo, and the residue was recrystallized from ethanol.
• a white crystalline substance was obtained which had a melting point of 119-420 C. It was identified to be 2-chloro-3-(2'-acetoxy-5-chloro-benzoylamino)-pyridine of the formula 1 Analysis.-C H Cl N O ;mol. wt. 325.2. Calculated: C, 51.71%; H, 3.10%; Cl, 21.81%; N, 8.62%. Found: C, 51.20%; H, 3.05%; Cl, 21.60%; N, 8.35%.
• the product had a melting point of 235-237 C. and was identified to be 2-chloro-3-(2'-hydroxy-naphthoylamino)-pyridine of the formula (b) 12 gm. of 2-chloro 3 (2'-hydroxy-naphthoylamino)-pyridine and 3.4 gm. of potassium hydroxide were dissolved in 200 cc. of absolute ethanol. 200 cc.
• reaction mixture was refluxed for one hour, allowed to cool, and then a solution of 16 gm. (0.4 mol) of sodium hydroxide in 100 cc. of water was added.
• the mixture was refluxed for thirty minutes accompanied by vigorous stirring, allowed to cool, and the two liquid phases Were separated.
• Thetoluene phase was extracted with dilute sodium hydroxide.
• the combined alkaline aqueous phases were filtered through activated charcoal. Carbon dioxide was passed through the filtrate, whereby a precipitate was formed which Was recrystallized first from isopropanol and then from cyclohex-ane.
• the product had a melting point of 140-142 C.
• Example 7 Preparation of 5,6-dihydro-6-oxo-8-tert. butyl-pyrido [2,3-b] [1,4] benzoxazepine (a) Using a procedure analogous to that described in Example 6(a), 2-chloro-3-(2-hydroxy-5 tert.butyl-benzoylamino)-pyridine, M.P. 154-156 C. (recrystallized from gasoline), was prepared from 2-chloro-3-aminopyridine and 2-hydroxy-5-tert.butyl-benzoic acid.
• Example 8 Preparation of 5,6-dihydro-6-oxo-9-methoxy-pyrido 2,3-b] 1,4] ben'zoxazepine (a) Using a procedure analogous to that described in Example 6(a), except that absolute dioxane was used as the solvent. medium in place of toluene, 2-chloro-3-(2- hydroxy 4 methoxy -'benzoylamino) pyridine, M.P. 193.5 C. (recrystallized from acetonitrile), was prepared from 2-chloro-3-amino-pyridine and 2-hydroxy-4-1nethoxybenzoic acid.
• Example 11 Preparation of 5,6-dihydro-6-oxo-9-amino pyrido[2,3-b] [1,4] benzoxazepine 46.0 gm. (0.3 mol) of 4-amino-s-a1icylic acid and 39.0 gm. (0.3 mol) of 2-chloro-3-amino-pyridine were stirred with 300 cc. of absolute dioxane, and the resulting suspension was admixed with 15.0 gm. (0.11 mol) of phosphorus trichloride. The resulting mixture was heated for one hour at 100 C., and was then allowed to cool. The precipitate formed thereby was separated by filtration,
• Example 12 Preparation of 5,6-dihydro-6-oxo-8-acetylpyrido[2,3-b] [1,4] benzoxazepine Using a procedure analogous to that described in Example 6, 5,6-dihydro-6-oxo-8-acetyl-pyrido[2,3-b] [1,4] benzoxazepine, M.P. 305 (recrystallized from 1,2,3,4- tetrahydronaphthalene), of the formula was prepared from 2-chloro-3-amino-pyridine and -acetyl-salicylic acid.
• the compounds according to the present invention that is, those embraced by Formula I above, have useful pharmacodynamic properties. More particularly, they exhibit-antipyretic, antiphlogistic, sedative and analgesic properties in warm-blooded animals.
• the compounds of the present invention are useful as intermediates in the preparation of other derivatives of 5,6-dihydro-6-oxo-pyridol[2,3-b] [l,4]benzoxazepines, namely, 5-alkyland S-aminoalkyl-substituted derivatives, which exhibit antipyretic, histaminolytic, reserpine-antagonistic, sedative, antiphlogistic, analgesic and antiemetic properties.
• S-substituted derivatives above referred to are prepared by converting a compound of the Formula 1 into a corresponding S-alkali metal compound according to known methods, which is then reacted with an alkylhalide or an aminoalkylhalide.
• the compounds according to the present invention are administered orally or parenterally as active ingredients in customary dosage unit compositions, that is, compositions in dosage unit form consisting essentially ofan inert pharmaceutical carrier and one dosage unit of the active ingredient, such as tablets, coated pills, syrups, solutions, suspensions, capsules, suppositories and the like.
• One dosage unit of the compounds according to the present invention is from to 200 mgm., preferably to mgm.
• Dosage unit compositions comprising a compound of the present invention as an active ingredient may also contain one or more additional active ingredients which supplement or potentiate the action of the pyridobenzoxazepine ingredient, especially an. analgesic or sedative, such as a codeine acid addition salt, 5-phenyl-5-ethylbarbituric acid or the like.
• analgesic or sedative such as a codeine acid addition salt, 5-phenyl-5-ethylbarbituric acid or the like.
• compositions comprising a compound of the present invention as an active antipyretic ingredient.
• the parts are parts by weight unless otherwise specified.
• Example 13 The tablet composition is compounded from the following ingredients:
• the pill core composition is compounded from the following ingredients:
• Example 15 The syrup composition is compounded from the following ingredients:
• sodium hydroxide and the codeine hydrochloride are dissolved in 10 parts of distilled water (solution 2).
• the menthol is dissolved in a mixture of the ethanol and the flavoring (solution 3).
• the sodium benzoate, the saccharin sodium and the certified food color are dissolved in'the remaining amount of distilled water (solution 4).
• Solution 2 solution 4 and solution 3 are added in that order to solution 1.
• the resulting syrup is filtered through a suitable filter, and then the pulverized pyridobenzoxazepine compound is added thereto.
• the finished syrup is homogenized.
• 10 cc. of syrup contain 10 mgm. of codeine hydrochloride and 50 mgm. of the pyridobenzoxazepine compound.
• Example 16 Coated pills with codeine phosphate
• the pill core composition is compounded from the following ingredients:
• Example 18 Suppositories with phenobarbital The suppository composition is compounded from the following ingredients:
• Example 19 Aqueous suspension for oral administration to children The suspension is compounded from the following ingredients:
• R is selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, lower alkanoyloxy, amino, lower alkanoyl amino and lower alkanoyl.
• R is selected from the group consisting of hydrogen, chlorine, alkyl of 1 to 4 carbon atoms, methoxy, amino, acetamino and acetyl.
• R is selected from the group consisting of hydrogen and methyl.
• the reactive derivative of the salicylic acid compound is selected from the group consisting of lower alkyl esters, acyl esters, halides and anhydrides.
• the reactive derivative of the salicylic acid compound is selected from the group consisting of lower alkyl esters, acyl esters, halides and anhydrides.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=7552363

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (2)

Citations (1)

• 0
  • GB GB1050565D patent/GB1050565A/en active Active
• 1964
  • 1964-03-20 DE DE1470361A patent/DE1470361C3/de not_active Expired
• 1965
  • 1965-02-24 CH CH249065A patent/CH453370A/de unknown
  • 1965-03-09 US US438374A patent/US3376289A/en not_active Expired - Lifetime
  • 1965-03-15 FR FR1602261D patent/FR1602261A/fr not_active Expired
  • 1965-05-26 FR FR18535A patent/FR4405M/fr not_active Expired

Patent Citations (1)

Also Published As

Similar Documents